Following the industry updates we've been sharing, I wanted to offer a few additional thoughts about where I believe things may be heading and a decision I've made regarding Dark Horse inventory. 🐎 FIRST, AN INVENTORY UPDATE As some of you may have noticed, certain hormonal and anabolic compounds have already been removed from Ready Inventory. I've also decided that once my remaining inventory is gone, I will not be replenishing these products. This is a deliberate decision about what I want to continue carrying as the industry evolves. Anyone looking for those hormoal and anabolic compounds should DM me directly. ⚡ MY OUTLOOK FOR 2027 I personally believe HGH and certain GLP-related peptides are going to become increasingly difficult to source and more expensive. Between the developments in China, increasing regulatory pressure, supply-chain disruptions, and Eli Lilly's ongoing litigation involving the GLP market, I don't see things getting easier anytime soon. And with additional court proceedings scheduled for 2027, I believe we're going to see further changes in how this industry operates. ⚡ THE INDUSTRY MAY HAVE HELPED CREATE ITS OWN PROBLEM There's another factor I believe deserves attention. The sheer saturation of peptide retailers, resellers, and promoters across social media has, in my opinion, put an enormous target on the entire peptide movement. What was once a relatively small, niche research and biohacking community has exploded into a highly visible commercial marketplace. Everywhere you look, there are new vendors, storefronts, social media groups, promotions, and people trying to get a piece of the business. The gray market has become not so gray anymore, particularly in the eyes of regulatory and enforcement agencies. And I think we're already seeing the consequences. Look at what's happening in the banking and payment-processing world. Credit card processing has become increasingly challenging for businesses operating in this space. Merchant accounts are being scrutinized, payment services are restricting certain transactions, and vendors are finding themselves with fewer conventional payment options.

I asked everyone what Dark Horse should investigate next. Looking back, I asked the wrong question. I don't need a list of subjects for me to research. We already have more research directions than we have time. What I'm interested in is what YOU are researching So, here's the question I should have asked: WHAT HAVE YOU BEEN DIGGING INTO? Bring to the community what you've actually been researching. Not simply a topic you'd like Dark Horse to research. Something you've been digging into yourself. Maybe it's a peptide, bioregulator, delivery method, pathway, study, protocol concept—or something completely outside the areas we've already discussed. What caught your attention? What have you learned so far? And what questions are you still trying to answer? You don't need to have it figured out. You don't need to write a research paper. And we certainly don't need to be experts. Just bring something to the table. We've covered a tremendous number of subjects. Some were intentionally high-level introductions—not deep dives—while others focused on going much deeper. Maybe one of them sent you down your own rabbit hole. If it did, tell us where it took you. I'd really like to see more people involved in the discussion and see us start learning from each other's research, rather than every conversation beginning with Dark Horse. So—what have YOU been digging into?

We've covered a LOT of ground in Dark Horse. Peptides. Mitochondrial health. Bioregulators. Immune function. Testing. Vendor quality. HGH. Research protocols. Tracking. And plenty of things in between. I've intentionally stayed away from making GLP-1s a major focus because there are already countless communities built almost entirely around them. But here's the thing. I don't want every discussion topic in this community coming from me. There are enough people here with different experiences, different interests and different research objectives that somebody has to be thinking: "Why haven't we talked about ______ yet?" So I'm putting this one on YOU. What do you want Dark Horse to investigate next? It could be a peptide we haven't discussed. A compound you've been seeing mentioned everywhere but don't really understand. Something related to aging, recovery, metabolism, sleep, cognition, inflammation, mitochondrial function, performance or longevity. A study you came across that you want someone to tear apart. Or something completely outside the areas we normally discuss that you think deserves a closer look. Drop ONE topic below. Don't worry about whether you know enough about it to start a discussion. That's the whole point. We'll do the digging together.

I'm beginning to research what I may want to run for my next bioregulator cycle, and I thought this would be a good real-world example of how I personally use my Stack Engine. But before I get into the two bioregulators I'm researching, there is an important part of how I approach these cycles. I don't believe a bioregulator cycle has to exist in isolation. Running peptides next to, before, after, or in conjunction with a bioregulator cycle can make perfect sense when everything being used is addressing the biological environment I'm trying to affect. I'm not drawing an artificial line between: Peptides over here. Bioregulators over there. Supplements somewhere else. That's not how I look at it. I start with the objective. What biological environment am I trying to affect? What systems are involved? What is happening within those systems as we age? And then: What job does each potential component perform? If a peptide addresses inflammation, mitochondrial function, metabolic function, tissue repair, cellular signaling or another factor that directly influences the environment I'm targeting, I want to know about it. If a bioregulator addresses a specific regulatory pathway within that same environment, I want to understand that too. Then I determine whether they belong together. The tool doesn't determine the objective. The objective determines the tools. And it brings me to what I'm currently researching. MY OBJECTIVE Healthy aging of the interconnected brain–immune system. Two bioregulators have my attention: Pinealon (EDR) and Thymogen (EW). But I'm not starting with: “These two sound good together. Let's stack them.” I'm trying to determine whether the biology actually supports putting them together. PRIMARY SYSTEM 1 — CNS / NEURONAL Pinealon (EDR) Glu–Asp–Arg My interest here is the nervous system and neuronal aging. What exactly is EDR doing at the cellular level? What does the research actually show regarding gene regulation, oxidative stress, apoptosis, inflammatory signaling, neuronal function and other age-related changes?

I came across the following post in another peptide group this morning. I'm reposting it exactly as it appeared: "H3H Happenings H3H Situation: NOT good. First raws were hard to get, then good raws were hard to get and now china has cracked down even harder on not allowing the sale or production of H3h. I truly cannot tell you if this is a permanent thing or how long this will be, but from what sources are saying it won’t be anytime soon. They, much like I, face imprisonment of loosing everything for merely stocking one item so most aren’t even risking it. They now have to hold a special license in order to purchase raws. With that being said I’ve done a hard inventory of what I have left. There’s no more ordered, no more in route, no hidden stash, and it will not ever be restocked. Less than 50 kits left of 24iu and 36iu and they’re currently listed under a24iu or a36iu. Once you see that sold out button—that’s it. This is such a good one, does so much good, but they’re yanking it out from under us. I even want to panic hoard and I have been. Even more so now." SO I WENT LOOKING. There is some truth behind what is being reported, but there are also some conclusions being drawn that I cannot currently validate. China does tightly regulate HGH and other peptide hormones. Growth Hormone (GH) is specifically included in China's 2026 prohibited-substances catalog, and production, sale, import and export of these substances are controlled. China also requires licensing and regulatory approval for legitimate manufacture and wholesale handling of peptide hormones. But from what I've read and can find that licensing requirement isn't new. What is important is that China introduced revised Drug Administration regulations in May 2026 and has been tightening manufacturing oversight, licensing, GMP compliance and traceability. So, it is certainly possible that manufacturers operating outside the legitimate pharmaceutical system are deciding that producing or handling HGH is no longer worth the regulatory risk.